Publications by authors named "R Kalil-Filho"

Article Synopsis
  • The discovery of RNA interference in 1998 led to the creation of siRNA drugs, including Patisiran, which targets a rare genetic disease called hereditary transthyretin amyloidosis.
  • Additional siRNA medications like Givosiran and inclisiran have shown positive results in treating genetic disorders and hypercholesterolemia, respectively, with ongoing research on their broader health impacts.
  • New siRNA therapies are being explored for cardiovascular conditions, aiming to reduce risk factors like lipoprotein(a) and angiotensinogen levels, with a hopeful outlook for their effectiveness in improving heart health and long-term safety in larger populations.
View Article and Find Full Text PDF

Background: This study investigates myocardial structural changes in stable coronary artery disease (CAD) patients with type 2 diabetes (T2D) using cardiac magnetic resonance (CMR) strain and T1 mapping.

Methods: A total of 155 stable CAD patients underwent CMR examination, including left ventricular (LV) morphology and function assessment, late gadolinium enhancement (LGE), and feature tracking (CMR-FT) for LV global longitudinal, circumferential, and radial strain. T1 mapping with extracellular volume (ECV) evaluation was also performed.

View Article and Find Full Text PDF

Obesity increases serum triglycerides and decreases high-density lipoprotein cholesterol (HDL-C). The objective is to explore some functions of HDL, cholesterol transfers and antioxidant, in subjects with grade I (G1-OB) and III (G3-OB) obesity and effects of bariatric surgery on G3-OB. Fifteen G3-OB patients (43 ± 6 years, BMI 49 ± 3 kg/m) were studied before and 1 year after bariatric surgery; 15 G1-OB (32 ± 2 years, 32 ± 2 kg/m) and 15 normal weight (NW) (38 ± 6 years, 22 ± 1 kg/m) were also studied.

View Article and Find Full Text PDF

Background: Oncological patients with coronary artery disease face an elevated risk of hemorrhagic and ischemic events following percutaneous coronary intervention. Despite medical guidelines recommending minimal dual antiplatelet therapy (DAPT) duration for patients with cancer, dedicated data on abbreviated DAPT in this population is lacking. This study aims to evaluate the occurrence of ischemic and hemorrhagic events in patients with cancer compared with other high-bleeding risk individuals.

View Article and Find Full Text PDF